US Medical Innovations (USMI) has obtained approval from the US Food and Drug Administration (FDA) for its Canady Flex RoboWrist device.

The approval enables the use of the new robotic surgery device in open and laparoscopic procedures in the country.

The device already secured approval for use in Asia, Europe and the Middle East.

It is mainly suitable for transection, dissection and suturing of tissue during open, endoscopic and minimally-invasive surgical procedures such as thoracic, general, urologic, gynecologic and laparoscopic surgeries.

USMI is providing the fully articulating motorised, 5mm hand-held surgical instrument with different end effectors including a needle driver, hook, scissors and dissector with 3° of freedom and 360° of rotation.

The device has a connector for the USMI XL-1000 electrosurgical generator, which provides the option to utilise the mono scissors or hook for electrosurgery.

Equipped with advanced automation and intelligent control systems, the device helps surgeons conduct intricate procedures with utmost accuracy.

Furthermore, the device optimises surgical workflows and enables surgeons to focus more on crucial decision-making.

It also assists with repetitive tasks to improve overall efficiency.

USMI CEO Jerome Canady said: “The Flex RoboWrist represents a significant advancement in laparoscopic surgical technology and will empower surgeons to achieve exceptional results and redefine the possibilities of laparoscopic surgical procedures.

“The flexible design provides motorised control of two movements that are essential to accessing surgical sites and laparoscopic suturing: bidirectional deflection and unlimited rotation of the distal jaws of the instrument.”